Cellect(US:QNRX)2025-11-06 21:18Financial Performance - The company reported a net loss of approximately $3.9 million for Q3 2025, compared to a net loss of approximately $2.3 million for the same period in 2024, reflecting an increase in R&D expenditures[11][16] - As of September 30, 2025, Quoin had approximately $5.4 million in cash, cash equivalents, and marketable securities, which, along with the recent funding, is expected to support operations into 2027[10][11] - Quoin's total operating expenses for Q3 2025 were approximately $4.0 million, compared to $2.5 million in Q3 2024[16] Research and Development - QRX003, the lead clinical asset, is set to commence pivotal studies for Netherton Syndrome in Q4 2025[1][4] - Research and development expenses for the nine months ended September 30, 2025, totaled approximately $6.7 million, up from $2.6 million in the same period in 2024[11][16] - The company received orphan drug designation from the FDA for QRX003, aimed at treating Netherton Syndrome[1][3] Funding and Financial Strategy - Quoin Pharmaceuticals closed a private placement financing of up to $105.3 million in October 2025, with initial funding of $16.6 million[1][4] - The company plans to utilize proceeds from the private placement for R&D, working capital, and potential future acquisitions[3][4] Marketing and Awareness - The NETHERTON NOW awareness campaign achieved over 1.5 million views within six months of its launch, significantly exceeding initial expectations[1][3] Leadership Changes - The appointment of Sally Lawlor as CFO is expected to strengthen the leadership team as the company prepares for commercialization[1][3]